Citadel Advisors
HEPA

Citadel Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Citadel Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-35
Closed -$69K – 14137
2021
Q2 		$69K Buy
35
+12
+52% +$22K ﹤0.01% 13169
2021
Q1 		$43K Sell
23
-3
-12% -$6.58K ﹤0.01% 12955
2020
Q4 		$56K Buy
+26
New +$67.4K ﹤0.01% 10527

Other funds holding HEPA

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citadel Advisors's HEPA Position: Q2 2025 in Review

Citadel Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q2 2025, closing a stake of 15,581 shares — an estimated $6.7K sold.

Citadel Advisors first reported a position in HEPA in Q4 2018 and held it in 13 quarters. The position peaked at $114K in Q2 2021. 4 funds tracked by Wall St. Rank hold HEPA as of Q2 2025.

  • Citadel Advisors reported no remaining Hepion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Citadel Advisors sold 15,581 Hepion Pharmaceuticals shares in Q2 2025, an estimated $6.7K.
  • Citadel Advisors first reported a position in Hepion Pharmaceuticals in Q4 2018 and held it in 13 quarters.
  • Citadel Advisors's Hepion Pharmaceuticals position peaked at $114K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q2 2025.

Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.